SeeThruEquity Initiates Research Coverage on Cardax, Inc. with a Target Price of $1.00
ACCESSWIRE - Mon Oct 06, 8:06AM CDT
New York, NY / ACCESSWIRE / October 6, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Cardax, Inc. (OTCQB: CDXI), Cardax is a development stage, life sciences company focused on introducing nutraceutical and pharmaceutical products aimed at reducing inflammation and oxidative stress.
Cardax Appoints Former Novartis, Bristol-Myers Squibb, and Boehringer Ingelheim Executives as Directors
Business Wire - Tue Jun 17, 7:01AM CDT
Cardax, Inc. ("Cardax"
OXGN: 1.59 (unch), ACT: 254.20 (-1.68), LXRX: 0.90 (+0.02), ONVO: 6.84 (+0.03), IDIX: 24.50 (+0.05), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66)